Literature DB >> 15741003

Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics.

Sergio A Strejilevich1, Ana Palatnik, Rubén Avila, Julián Bustin, Julieta Cassone, Soledad Figueroa, Mariana Gimenez, Gabriel A de Erausquin.   

Abstract

We compared symptom severity and quality of life (QOL) in schizophrenic patients adequately treated with typical antipsychotics (TAP) or clozapine (CZP). Groups did not differ in symptom severity or QOL. Clozapine caused fewer extrapyramidal symptoms. Negative and extrapyramidal symptoms predicted QOL. Similar outcome in both groups suggests a common ceiling to antipsychotic efficacy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15741003     DOI： 10.1016/j.psychres.2004.10.009

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  10 in total

1.  Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis.

Authors:  Shaun M Eack; Christina E Newhill
Journal:  Schizophr Bull       Date:  2007-01-04       Impact factor: 9.306

2.  Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.

Authors:  Mara Balda; Maria Calvó; Eduardo Padilla; Gonzalo Guerrero; Juan Molina; Nestor V Florenzano; Danielle Kamis; Javier I Escobar; C Robert Cloninger; Gabriel de Erausquin
Journal:  Focus (Am Psychiatr Publ)       Date:  2015

3.  Oral antipsychotic prescribing and association with neighbourhood-level socioeconomic status: analysis of time trend of routine primary care data in England, 2011-2016.

Authors:  Kurt Buhagiar; Mustafa Ghafouri; Mrinalini Dey
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-10-19       Impact factor: 4.328

4.  Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia.

Authors:  Assefa Kumsa; Shimelis Girma; Bezaye Alemu; Liyew Agenagnew
Journal:  Clin Pharmacol       Date:  2020-12-01

5.  Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia.

Authors:  Ashley S Roseman; John Kasckow; Ian Fellows; Katerine Osatuke; Thomas L Patterson; Somaia Mohamed; Sidney Zisook
Journal:  Int J Geriatr Psychiatry       Date:  2008-07       Impact factor: 3.485

6.  Domains and determinants of quality of life in schizophrenia and systemic lupus erythematosus.

Authors:  Rajiv Radhakrishnan; Jayakumar Menon; Milanduth Kanigere; Mysore Ashok; Vineeta Shobha; R B Galgali
Journal:  Indian J Psychol Med       Date:  2012-01

7.  Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic.

Authors:  Assefa Kumsa; Liyew Agenagnew; Beza Alemu; Shimelis Girma
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

8.  Relationship between social and cognitive functions in people with schizophrenia.

Authors:  Takeo Tominaga; Masahito Tomotake; Tomoya Takeda; Yoshinori Ueoka; Tsunehiko Tanaka; Shin-Ya Watanabe; Naomi Kameoka; Masahito Nakataki; Shusuke Numata; Yumiko Izaki; Satsuki Sumitani; Hiroko Kubo; Yasuhiro Kaneda; Tetsuro Ohmori
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-30       Impact factor: 2.570

9.  What does anisotropy measure? Insights from increased and decreased anisotropy in selective fiber tracts in schizophrenia.

Authors:  L M Alba-Ferrara; Gabriel A de Erausquin
Journal:  Front Integr Neurosci       Date:  2013-03-11

10.  Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC.

Authors:  Carole Siani; Christian de Peretti; Aurélie Millier; Laurent Boyer; Mondher Toumi
Journal:  Qual Life Res       Date:  2015-09-18       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.